In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells
Open Access
- 4 November 2010
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 116 (18) , 3505-3516
Abstract
Cells from the mononuclear phagocyte system (MPS) act as systemic and local amplifiers that contribute to the progression of chronic inflammatory disorders. Transforming growth factor-β–activated kinase 1 (TAK1) is a pivotal upstream mitogen-activated protein kinase-kinase-kinase acting as a mediator of cytokine expression. It remains critical to determine in vivo the implication of TAK1 in controlling the innate immune system. Here, we describe a vehicle tailored to selectively deliver siRNAs into MPS cells after intravenous administration, and validate in vivo the potential of the RNAi-mediated TAK1 knock down for immunomodulation. In a mouse model of immune-mediated inflammatory disorder, we show that anti-TAK1 siRNA lipoplexes efficiently alleviate inflammation, severely impair the downstream c-Jun N-terminal kinase and nuclear factor-κB signaling pathways, and decrease the expression of proinflammatory mediators. Importantly, the systemic TAK1 gene silencing decreases the frequency of Th1 and Th17 cells, both mediating autoimmunity in experimental arthritis, demonstrating the immunomodulatory potential of TAK1. Finally, in vitro inhibition of TAK1 in myeloid cells decreases interferon-γ–producing T cells, suggesting that a delivery sys-tem able to target MPS cells and to silence TAK1 impacts on pathogenic T effector cells in autoimmunity.Keywords
This publication has 45 references indexed in Scilit:
- TAK1 is an essential regulator of BMP signalling in cartilageThe EMBO Journal, 2009
- Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammationNature, 2009
- The promises and pitfalls of RNA-interference-based therapeuticsNature, 2009
- Interaction between TAK1–TAB1–TAB2 and RCAN1–calcineurin defines a signalling nodal control pointNature Cell Biology, 2009
- A potent and selective p38 inhibitor protects against bone damage in murine collagen‐induced arthritis: a comparison with neutralization of mouse TNFαBritish Journal of Pharmacology, 2008
- TAK1 Is a Central Mediator of NOD2 Signaling in Epidermal CellsJournal of Biological Chemistry, 2008
- A critical role of RICK/RIP2 polyubiquitination in Nod‐induced NF‐κB activationThe EMBO Journal, 2007
- Cytokines in the pathogenesis of rheumatoid arthritisNature Reviews Immunology, 2007
- Essential role of TAK1 in thymocyte development and activationProceedings of the National Academy of Sciences, 2006
- TAK1 Is a Master Regulator of Epidermal Homeostasis Involving Skin Inflammation and ApoptosisJournal of Biological Chemistry, 2006